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Abstract
Background: Pseudomyxoma peritonei (PMP) is a rare condition characterized by mucinous
tumors, disseminated intra-peritoneal implants, and mucinous ascites. So far its diagnosis remains
challenging to most clinicians.
Case presentation: A 55-year-old male patient had suffered from acute onset of abdominal pain
and abdominal distension for one day prior to his admission. Physical examination revealed
tenderness over the right lower quadrant of the abdomen without diffuse muscle guarding. A large
amount of ascites was identified by abdominal computed tomography (CT) scan. Paracentesis
showed the appearance of sticky mucinous ascites. He underwent laparotomy under the
impression of pseudomyxoma peritonei. There was a lot of mucinous ascites, one appendiceal
tumor and multiple peritoneal implants disseminated from the subphrenic space to the recto-
vesicle pouch. Pseudomyxoma Peritonei caused by mucinous adenocarcinoma of appendiceal
origin, was confirmed by histopathology. We performed an excision of the appendiceal tumor
combined with copious irrigation and debridement. After the operation, he received 10 cycles of
systemic chemotherapy with FOLFOX4 regimen, without specific morbidity. Follow-up of
abdominal CT and colonoscopy at post-operative 17 months showed excellent response without
evidence of local recurrence or distal metastasis. He made an uneventful recovery (up to the
present) for 21 months after the operation.
Conclusion: This case report emphasizes the possible new role of systemic chemotherapy in the
treatment of patients with this rare clinical syndrome.
Background
Pseudomyxoma peritonei (PMP) is a rare condition char-
acterized by mucinous tumors, disseminated intra-perito-
neal implants, and mucinous ascites. It may represent a
pathologic diagnostic term to both benign and malignant
mucinous neoplasms that produce abundant extracellular
mucin. Therefore, poorly predictable clinical course and
variable prognosis could be expected. A definitive diagno-
sis of PMP requires the presence of mucinous neoplastic
epithelium and mucinous ascites, and may also include
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detailed understanding of PMP based on the clinical case
series, there is still some debate about its clinical behavior,
pathogenesis, and treatment strategy. We report our clini-
cal experience concerning systemic chemotherapy
(FOLFOX4 regimen) for one case of pseudomyxoma peri-
tonei secondary to appendiceal mucinous adenocarci-
noma and review the literature.
Case presentation
A 55-year-old male patient had suffered from acute onset
of abdominal pain and abdominal distension for one day
prior to his admission. He had previously been healthy
without any specific underlying disease. Unfortunately,
nausea and vomiting were noted twelve hours after his
onset of abdominal pain. There was no fever, chills, or
diarrhea. The characteristics of his abdominal pain
included steady dull pain over the periumbilical and
lower abdomen. On general physical examination, we
found the patient presenting abdominal distension,
hypoactive bowel sound, and diffuse tenderness over the
whole abdomen, and localized muscle guarding over the
right lower abdomen. Laboratory data showed predomi-
nant neutrophil (94%) without leukocytosis (white blood
cell count 9160/μl). A large amount of ascites was identi-
fied by abdominal sonography and paracentesis was
done. It showed the appearance of sticky mucinous ascites
with the result of monocyte predominant in the ascites
study. Abdominal computed tomography (CT) showed
mucin septations (Fig. 1), thickening of the omentum and
scalloping of hepatic and splenic margins (Fig. 2), which
were compatible with the characteristics of the image of
pseudomyxoma peritonei (PMP). He underwent laparot-
omy and much yellowish-greenish jelly-like material in
the peritoneal cavity was noted (Fig. 3). Besides, one
appendiceal tumor and multiple peritoneal implants dis-
seminated from subphrenic space to the recto-vesicle
pouch. Intra-operative frozen section of appendiceal
tumor and one of the peritoneal implants confirmed
mucinous adenocarcinoma of the appendix (Fig. 4 &5).
The diagnosis of PMP was confirmed by the final histopa-
thology. Instead of the aggressive peritonectomy proce-
dures, we performed excision of the appendiceal tumor;
local debridement and copious irrigation. After the oper-
ation, he received 10 cycles of systemic chemotherapy
with FOLFOX4 regimen (oxaliplatin 85 mg/m2 as a two-
hour infusion on day 1, leucovorin 200 mg/m2 as a two-
hour infusion concurrently with oxaliplatin on day 1, fol-
lowed by a bolus of 5-FU 400 mg/m2 and continuous
infusion of 5-FU 600 mg/m2 over 22 hours), without spe-
cific morbidity [2]. Abdominal CT and colonoscopy at
post-operative 17 months showed complete response
without evidence of local recurrence or distal metastasis
(Fig. 6 &7). Follow-up serum carcinoembryonic antigen
(CEA) level also showed no progressive activity of his dis-
ease. He remains well currently, and receives follow-up
regularly in our outpatient clinic.
CT scan of abdomen showing pseudomyxoma peritonei with mucin septations (arrows)Figure 1
CT scan of abdomen showing pseudomyxoma peri-
tonei with mucin septations (arrows).
CT scan of abdomen showing pseudomyxoma peritonei with scallopi g of hepatic margin (arrows)Figure 2
CT scan of abdomen showing pseudomyxoma peri-
tonei with scalloping of hepatic margin (arrows).Page 2 of 7
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Pseudomyxoma peritonei (PMP) is a rare clinical syn-
drome with an estimated incidence of approximately one
per million per year and preferentially affects women (2–
3 times more common than men) [3,4]. Since Werth [5]
first described PMP produced by an ovarian neoplasm
Multiple peritoneal implants (arrows) over visceral perito-neumFigure 3
Multiple peritoneal implants (arrows) over visceral 
peritoneum. Mucinous ascites with yellowish-greenish 
materials (arrow head) in peritoneal cavity.
The pathological findings of the resected appendixFigure 4
The pathological findings of the resected appendix. 
Mucinous adenocarcinoma (arrows) exhibiting abundant 
acellular mucin pooling (arrow head), with scarce well-differ-
entiated mucin producing epithelium embedded in a fibrous 
matrix or as lining epithelium.
The pathological findings of the resected appendix extra-cel-lular mucin us materials (arrow) showing light blue in color dist ibuted in fibrous stromaFigure 5
The pathological findings of the resected appendix 
extra-cellular mucinous materials (arrow) showing 
light blue in color distributed in fibrous stroma.
CT scan of abdomen – postoperative 17 months, compared with Fig 1Figure 6
CT scan of abdomen – postoperative 17 months, 
compared with Fig 1. No local recurrence or metastatic 
lesion is identified.Page 3 of 7
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with an appendiceal mucocele, there have been many
reports focusing on the pathogenesis, diagnosis, treat-
ment and prognosis of PMP.
The primary origin of the mucinous peritoneal implants
in PMP has remained controversial for a long time. Some
reports indicated that ovarian tumor is more likely to be
the primary neoplasm of PMP [3,7], however, others favor
the appendiceal tumor as the answer [4,8,9]. Because
immunohistochemical stains and molecular genetic stud-
ies both show the evidence of these tumors being second-
ary to appendiceal neoplasms [10-12], most people agree
that the primary tumor of PMP is predominately a muci-
CT scan of abdomen – postoperative 17 months, compared with Fig 2Figure 7
CT scan of abdomen – postoperative 17 months, compared with Fig 2. No local recurrence or metastatic lesion is 
identified.Page 4 of 7
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primary sites being reported include: colorectum, gall-
bladder, pancreas, urachus, urinary bladder, breast and
lung, but these are uncommon [13,14]. PMP is character-
ized by an abundant amount of mucinous ascites pro-
duced by adenomucinous tumor cells in implants on
peritoneal surfaces. These implants are the final stage of a
distribution process following the rupture of the muci-
nous neoplasm. The key associated finding is the presence
of epithelium outside the appendix in association with
the mucin and the peritoneal implants [1].
Ronnett et al [15] first described a widely accepted and
useful definition of PMP. They classified PMP into three
pathological subtypes with different pathological charac-
teristics and different prognosis: disseminated peritoneal
adenomucinosis (DPAM), peritoneal mucinous carcino-
matosis (PMCA), and an intermediate subtype (PMCA-I).
Histopathologically, DPAM is characterized by an abun-
dance of mucus with focally adenomucinous epithelium
without atypia or mitotic activity. In contrast to this,
PMCA is characterized by peritoneal tumor composed of
more abundant mucinous tumor cells with the architec-
ture and cytological features of carcinoma. Finally, the
intermediate subtype PMCA-I is characterized by an abun-
dance of DPAM lesions, but with focal areas with PMCA
lesions [15,16].
Besides the histopathological difference, their clinical
behaviors are also quite different. DPAM remains poten-
tially non-invasive and stays localized to the abdomen
without metastatic behavior. In contrast to this, PMCA
behaves with invasive and metastatic potential, as is char-
acteristic of mucinous adenocarcinoma. Patients with
PCMA are associated with the possibilities of liver, lung
and lymph node metastatic disease [17].
As symptoms remain non-specific, PMP presents a great
diagnostic challenge to clinicians. A precise diagnosis is
difficult due to the lack of specific symptoms in the early
stages of the disease. The most important symptom is a
gradually increasing abdominal girth. Patients may
present a typical "jelly belly" appearance [18]. Sometimes
patients present symptoms mimicking appendicitis with
intra-operative identification of a perforated appendiceal
mucocele. In other cases, they present an inguinal herni-
ated sac or an ovarian mass [18]. For 30% of female
patients, the first symptom is an ovarian mass [16].
Routine laboratory studies are seldom helpful in making
this diagnosis. Ultrasound is useful for initial establish-
ment of the diagnosis. Echo-guided paracentesis may
reveal mucinous ascites. Abdominal computed tomogra-
phy (CT) scan may demonstrate the characteristics of
mucinous ascites by analyzing the density properties
(Hounsfield Units [H.U.]), as it is significantly higher (5–
20 H.U.) than normal ascites (0 H.U.) [16]. CT may also
show the characteristic of "scalloping effect" on the sur-
face of the visceral organs resulting from compression by
the viscous mucinous secretions [1]. In the majority of
cases, however, PMP is often an unexpected finding of
laparoscopy or exploratory laparotomy [19].
When mucinous tumors on the peritoneal surface or
mucinous ascites are visualized on CT or during abdomi-
nal surgery, treatment of PMP should be performed since
untreated PMP patients will eventually suffer from intesti-
nal obstruction and mortality [20]. In spite of the contro-
versial standard treatment strategies for PMP, the current
mainstay of the treatment remains surgical resection of
the lesions. Alternative non-surgical treatment, such as:
peritoneal washing with 5% dextrose and systemic chem-
otherapy, have been reported; however, their roles in PMP
are still uncertain because of the limited case number and
short follow-up time [21,22].
Repeated cytoreductive surgical de-bulking procedures as
treatment for PMP have been described in earlier litera-
tures. Since the 1990s, a new combined treatment
approach was introduced by Sugarbaker et al [23]. They
defined it as peritonectomy procedures in combination
with intra-operative hyperthermic intra-peritoneal chem-
otherapy (HIPEC). Now this new combination treatment
is increasingly performed as treatment for PMP patients,
with promising results [24,25]. The available evidence
suggests that cytoreductive surgery with perioperative
intraperitoneal chemotherapy should replace serial de-
bulking as the standard of care for patients with peritoneal
spread of appendiceal epithelial neoplasms [20]. PMCA
behaves like peritoneal carcinomatosis from the original
colorectal adenocarcinoma; however, its poor prognosis
in comparison with DPAM after the similar management
by cytoreductive surgery and HIPEC was still demon-
strated in the two studies conducted by Sugarbaker et al
[26]. and Smeenk et al [27]. Moreover, Verwaal et al, also
showed a similar result in their randomized study, that
patients with peritoneal carcinomatosis of colorectal can-
cer (CRC) origin combined with cancer implant involve-
ment of six or more regions of the abdominal cavity, got
little survival benefit after the cytoreductive surgical pro-
cedures and intra-operative HIPEC [28].
Herein, further clinical trials with investigations of differ-
ent treatment strategies for patients with PMCA, are still
needed. This contributes to the application of systemic
chemotherapy for the patient in our case report since the
new therapeutic agent Oxaliplatin and its combination
with 5-fluorouracil/leucovorin (FOLFOX4 regimen) has
been used widely as first-line treatment in patients with
advanced CRC, and the promising results in these patientsPage 5 of 7
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[29,30].
The effect of systemic chemotherapy in PMP seems ques-
tionable. Jones et al [22] reported their experience in the
treatment of pseudomyxoma peritonei of ovarian origin
with cisplatinum, doxorubicin, and cyclophosphamide,
with excellent responses. On the other hand, Smeenk et al
[31] reported the poor response of six patients (3 patients
with DPAM, another 3 patients with PMCA-I, and all 6
patients with lesions diffusely spread throughout the
abdomen) after 5-FU based systemic chemotherapy, and
subsequent poor prognosis was noted in the study.
Regarding the benefit of new therapeutic agents (includ-
ing Capecitabine, Oxaliplatin, Irinotecan and Bevacizu-
mab) and modern schedules for patients with metastatic
CRC, clinical experience with the use of these agents for
PMP are still absent, and it is questionable whether they
will do any better in this situation, especially for patients
with PMCA. Due to the limited experience and indetermi-
nate effects of systemic chemotherapy in PMP, some stud-
ies still suggest that systemic therapy should be reserved
for a palliative setting in patients with recurrent or pro-
gressive disease [20,32].
Because of the high grade mucinous adenocarcinoma of
the appendix with disseminated peritoneal lesions both
confirmed by histopathology, instead of the treatment
strategies (including aggressive peritonectomy proce-
dures), we used oxaliplatin/5-FU/leucovorin combina-
tion systemic chemotherapy (FOLFOX4 regimen) in our
patient after less invasive surgery, as the treatment for the
metastatic colorectal cancer. After 10 cycles of FOLFOX4
chemotherapy, excellent response was achieved. Colonos-
copy and abdominal CT scan 17 months after the opera-
tion both showed no evidence of development of local
recurrent or metastatic lesions. The patient had an une-
ventful recovery up to now without any disease-related
morbidity. We believe that our experience is one of the
few reports about effective treatment of PMP with sys-
temic chemotherapy. More clinical experience and further
studies are still needed for determination of the benefit of
systemic chemotherapy for these patients.
Conclusion
We report our clinical experience regarding the use of sys-
temic chemotherapy (FOLFOX4 regimen) for one case of
pseudomyxoma peritonei secondary to mucinous adeno-
carcinoma of the appendix. This case report emphasizes
the possible new role of systemic chemotherapy in the
treatment of patients with this rare clinical syndrome.
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